Efficacy of neoadjuvant chemotherapy with FOLFOX scheme in treatment of advanced gastric carcinoma

Abstract

Objective To analyze the efficacy of neoadjuvant chemotherapy with FOLFOX scheme in treatment of advanced gastric carcinoma. Methods Eighty patients with advanced gastric carcinoma in the Central People’s Hospital of Zhanjiang from January 2017 to April 2018 were selected. And they were divided into two groups according to the randomized controlled method. The control group (40 cases) underwent laparoscopic radical gastrectomy; the observation group (40 cases) was given neoadjuvant chemotherapy with FOLFOX scheme before laparoscopic radical gastrectomy. The clinical efficacy, R0 resection rate, vascular endotbelial growth factor (VEGF) and complications were compared between the two groups. Results The total effective rate and R0 resection rate in observation group were higher than those in control group (P 0.05). Conclusions Neoadjuvant chemotherapy with FOLFOX scheme in treatment of advanced gastric carcinoma has definite short-term efficacy. It can increase R0 resection rate, regulate the level of VEGF, inhibit the development of disease, and reduce postoperative complications. Key words: Advanced gastric carcinoma; FOLFOX scheme; Neoadjuvant chemotherapy; Short-term efficacy; Vascular endotbelial growth factor